Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-line Followed by Second-line Sunitinib Versus Sunitinib as First-line Followed by Second-line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma.
Brief Summary: This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.


Options:
A: Arm Label: Arm I (sunitinib malate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Sunitinib Malate | Arm Label: Arm II (cabozantinib s-malate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Drug: Cabozantinib S-malate, Procedure: Computed Tomography | Arm Label: Arm III (crizotinib closed to accrual 12/5/18); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Crizotinib | Arm Label: Arm IV (savolitinib closed to accrual 12/5/18); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Savolitinib | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: PROCEDURE; Name: Bone Scan; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm II (cabozantinib s-malate) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Crizotinib; Assigned to Arm(s): Arm III (crizotinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Savolitinib; Assigned to Arm(s): Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Sunitinib Malate; Assigned to Arm(s): Arm I (sunitinib malate)
B: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
C: Arm Label: LY2510924 + Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: LY2510924, Drug: Sunitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: LY2510924; Assigned to Arm(s): LY2510924 + Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): LY2510924 + Sunitinib, Sunitinib
D: Arm Label: everolimus 1L/sunitinib 2L; Type: EXPERIMENTAL; Interventions: Drug: everolimus, Drug: sunitinib | Arm Label: sunitinib 1L/everolimus 2L; Type: ACTIVE_COMPARATOR; Interventions: Drug: everolimus, Drug: sunitinib | Intervention Type: DRUG; Name: everolimus; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L

Answer: D